KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Investments (2016 - 2023)

Historic Long-Term Investments for Pacira BioSciences (PCRX) over the last 10 years, with Q4 2023 value amounting to $2.4 million.

  • Pacira BioSciences' Long-Term Investments fell 9352.31% to $2.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.4 million, marking a year-over-year decrease of 9352.31%. This contributed to the annual value of $2.4 million for FY2023, which is 9352.31% down from last year.
  • According to the latest figures from Q4 2023, Pacira BioSciences' Long-Term Investments is $2.4 million, which was down 9352.31% from $8.3 million recorded in Q1 2023.
  • Pacira BioSciences' Long-Term Investments' 5-year high stood at $95.5 million during Q4 2020, with a 5-year trough of $2.4 million in Q4 2023.
  • Moreover, its 5-year median value for Long-Term Investments was $35.0 million (2020), whereas its average is $37.0 million.
  • Its Long-Term Investments has fluctuated over the past 5 years, first skyrocketed by 148413.49% in 2019, then tumbled by 9352.31% in 2023.
  • Quarter analysis of 5 years shows Pacira BioSciences' Long-Term Investments stood at $64.8 million in 2019, then soared by 47.32% to $95.5 million in 2020, then crashed by 63.37% to $35.0 million in 2021, then rose by 6.4% to $37.2 million in 2022, then crashed by 93.52% to $2.4 million in 2023.
  • Its Long-Term Investments was $2.4 million in Q4 2023, compared to $8.3 million in Q1 2023 and $37.2 million in Q4 2022.